Ernexa Therapeutics (ERNAW) Current Assets (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Current Assets data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Current Assets rose 352.1% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 352.1% YoY) and the FY2025 annual result came in at $3.1 million, up 33.21% from the prior year.
• Current Assets grew to $10.0 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $25.1 million in Q1 2022 to a low of $2.2 million in Q1 2025.
• A 5-year average of $8.5 million and a median of $6.2 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets sank 82.25% — and 2026, when it jumped 352.1%.
• Tracing ERNAW's Current Assets over 5 years: stood at $13.7 million in 2022, then decreased by 29.84% to $9.6 million in 2023, then plunged by 75.5% to $2.4 million in 2024, then surged by 33.21% to $3.1 million in 2025, then surged by 219.06% to $10.0 million in 2026.
• The last three Current Assets figures came in at $10.0 million (Q1 2026), $3.1 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.